Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
European Journal of Cancer2013Vol. 49(18), pp. 3821–3830
Citations Over TimeTop 1% of 2013 papers
Robert J. van Soest, Martin E. van Royen, Ellen S. de Morrée, J.M. Moll, Wilma J. Teubel, Erik A.C. Wiemer, Ron H.J. Mathijssen, Ronald de Wit, Wytske M. van Weerden
Related Papers
- → Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer(2019)639 cited
- → Treatment sequencing in metastatic castrate-resistant prostate cancer(2014)44 cited
- → Real-life Data on First- and Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer With Abiraterone, Enzalutamide and Cabazitaxel – A multicentric Study From Portugal(2024)1 cited
- → Re:Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer(2020)
- → Re: Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer(2020)